Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Nucl Med Biol. 2016 Jul 30;43(12):812–817. doi: 10.1016/j.nucmedbio.2016.07.008

Figure 4.

Figure 4

Immunohistochemical staining demonstrated minimal IGF2R-staining intensity following treatment with 188Re-MEM-238 (A), moderate IGF2R-staining following treatment with 188Re-MOPC21 (B), and robust IGF2R-staining in both tumors treated with unlabeled MEM-238 (C) or in tumor untreated (D). Findings suggest that OS cells expressing IGF2R have been killed by the RIT treatment.